SHPH Stock Summary and Trading Ideas (Shuttle Pharmaceuticals Holdings | NASDAQ:SHPH)

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.

Shuttle Pharmaceuticals Holdings trades on the NASDAQ stock market under the symbol SHPH.

As of July 17, 2026, SHPH stock price declined to $3.16 with 114,064 million shares trading.

SHPH has a beta of 2.44, meaning it tends to be more sensitive to market movements. SHPH has a correlation of 0.07 to the broad based SPY ETF.

SHPH has a market cap of $1.85 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, SHPH traded as high as $2,100.00 and as low as $2.71.

SHPH has underperformed the market in the last year with a price return of -92.0% while the SPY ETF gained +19.5%. SHPH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -69.0% and -11.7%, respectively, while the SPY returned +4.9% and -0.2%, respectively.

SHPH support price is $3.12 and resistance is $3.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SHPH shares will trade within this expected range on the day.